sb 203580 has been researched along with naringin in 3 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (naringin) | Trials (naringin) | Recent Studies (post-2010) (naringin) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 925 | 25 | 639 |
| Protein | Taxonomy | sb 203580 (IC50) | naringin (IC50) |
|---|---|---|---|
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | 7.6785 | |
| Aromatase | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, H; Huang, R; Li, S; Wu, K; You, Q | 1 |
| Chen, J; Guo, R; Huang, R; Li, S; Tian, L; Wu, K; Yan, H; You, Q | 1 |
| Aroui, S; Chtourou, Y; Fetoui, H; Kenani, A; Laajimi, A; Meunier, AC; Najlaoui, F | 1 |
3 other study(ies) available for sb 203580 and naringin
| Article | Year |
|---|---|
Naringin inhibits high glucose-induced cardiomyocyte apoptosis by attenuating mitochondrial dysfunction and modulating the activation of the p38 signaling pathway.
Topics: Animals; Apoptosis; Cell Line; Flavanones; Glucose; Imidazoles; Matrix Metalloproteinases; Mitochondria, Heart; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridines; Rats; Signal Transduction | 2013 |
Naringin inhibits ROS-activated MAPK pathway in high glucose-induced injuries in H9c2 cardiac cells.
Topics: Acetylcysteine; Animals; Anthracenes; Apoptosis; Butadienes; Cell Line; Cell Survival; Enzyme Inhibitors; Flavanones; Fruit; Glucose; Hyperglycemia; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Mitochondria; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; Nitriles; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Plant Extracts; Pyridines; Rats; Reactive Oxygen Species | 2014 |
Naringin inhibits the invasion and migration of human glioblastoma cell via downregulation of MMP-2 and MMP-9 expression and inactivation of p38 signaling pathway.
Topics: Cell Line, Tumor; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Flavanones; Glioblastoma; Humans; Imidazoles; Immunoblotting; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2016 |